We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis.
- Authors
Nadwi, Huda; Janaini, Murad; Zammo, Mohammed; Cheikh, Mohamed; Almoallim, Hani
- Abstract
Secukinumab, "an IL-17 antagonist", is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a case of a new-onset anterior uveitis after 6 months of starting secukinumab in a 47-year-old male, HLA-B27 positive AS patient. He had a long-standing history with the disease over 25 years. He was treated in the past with methotrexate then adalimumab and later on with etanercept. He had no history of uveitis during all of this time. The uveitis was mild and treated conventionally with local measures while secukinumab was maintained. After a close follow-up, the uveitis had completely resolved. Is this part of the original disease or a possible side effect from secukinumab?
- Subjects
ANKYLOSING spondylitis; IRIDOCYCLITIS; UVEITIS; DRUG side effects
- Publication
International Medical Case Reports Journal, 2020, Vol 13, p331
- ISSN
1179-142X
- Publication type
Article
- DOI
10.2147/IMCRJ.S265812